HPM faculty includes full-time professors at the forefront of their academic fields along with senior industry professionals who are subject matter experts within their sector. Faculty are accessible and actively involved in all aspects of the student experience.
Professor Chan teaches the MBA core Operations Management course and the MBA electives, The US Healthcare System: Structures and Strategies; Healthcare Management, Design, and Strategy; and The Analytics Advantage. Her research is in the area of healthcare operations management. Her primary focus is in data-driven modeling of healthcare systems. Her research combines empirical and mathematical modeling to develop evidence-based approaches to improve patient flow.
Linda Green is the Cain Brothers and Company Professor Emerita of Healthcare Management at Columbia Business School. She is also the Faculty Director of the Healthcare and Pharmaceutical Management Program at the business school.
Professor Cramer spent more than 25 years in the healthcare, pharmaceutical, and financial services sectors. He was Managing Director at Merrill Lynch in the Global Healthcare Investment Banking Group, and Managing Director at JPMorgan in the Corporate Finance Group providing M&A services and financing to global healthcare enterprises. Earlier, Prof. Cramer was Vice President, Corporate Planning & Development for Merck & Co., Inc. with worldwide responsibilities for strategic planning and business development.
Jing Dong is the DeRosa Family Associate Professor in the Decision, Risk, and Operations division at the Graduate School of Business, Columbia University. Her primary research interests are in applied probability and stochastic simulation, with an emphasis on applications in service operations management. Her current research focuses on developing data-driven stochastic modeling to improve patient flow in hospitals.
Robert Essner is the retired chairman and CEO of Wyeth, which was one of the world's leading research-based pharmaceutical companies. He led the transformation of Wyeth into a science-based industry leader with strong positions in drugs, biotechnology, vaccines, nonprescription products and animal health. During his more than 30 years in the industry, Mr. Essner served as chairman of both U.S. and global pharmaceutical organizations.
Raymond G. Falci currently serves on several healthcare boards and is an adjunct professor at Columbia Business School, having previously worked on Wall Street for 20+ years. Mr. Falci was a Managing Director at Cain Brothers from 2006 to 2016, serving on the Executive Committee and co-heading the firm’s Services & Technology practice. Ray’s banking focus included Healthcare IT and Revenue Cycle Management as well as healthcare distribution, specialty pharmacy and PBMs. Prior to joining Cain Brothers, Mr.
M. Jamil is a commercial leader in the Pharmaceutical industry with two decades of strategic and operational experience in matrix organizations across geographies, Jamil has extensively worked with clinical development teams to commercialize breakthrough therapeutics, including the first small molecule targeted therapy and the first aPD-1 immunotherapy. Jamil is currently working at Merck & Co and is responsible for the commercialization of oncology pipeline assets. He is also an adjunct Professor at Columbia Business School in New York.
Efrem Kamen is Managing Member at Pura Vida Investments, a life sciences investment firm he co-founded in 2012. The firm has significant investments across the healthcare universe, including Medical Technology, Life Science Tools and Biotechnology.
Frank R. Lichtenberg is Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business Economics at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Neal Masia is an Adjunct Professor of Business and Economics at Columbia University and serves as a consultant and advisor to a variety of healthcare companies and healthcare-focused investment firms. Neal spent nearly 18 years rising through the ranks at Pfizer Inc, most recently as Chief Economist and Vice President of Patient and Health Impact.
Ezra Mehlman is a managing partner at Health Enteprise Partners, a healthcare IT and services focused growth equity firm whose investors include some of the leading hospital systems and health plans across the country.
Dave Tamburri is a Managing Partner of Health Enterprise Partners, L.P. Prior to joining HEP in 2009, Dave was a Vice President for Susquehanna Growth Equity, a private equity group focused on growth stage technology companies. He was formerly the President and Chief Operating Officer of Onward Healthcare, Inc., a Welsh, Carson, Anderson & Stowe portfolio company. Prior to Onward, Dave was an Executive Vice President of Pinnacor, Inc., a General Atlantic portfolio company, which went public.
Peter Tollman is Senior Partner Emeritus at Boston Consulting Group. He's also Senior Advisor to the firm and, previously, was Managing Director and Senior Partner in the firm's Boston office. He led BCG's CEO Advisory Practice globally, served as global leader of BCG’s Biopharmaceutical Practice, and led its People and Organization Practice in the Americas. He was also a BCG Fellow, a prestigious thought-leadership post.
Dr. John W. Rowe is the Julius B. Richmond Professor of Health Policy and Aging at the Columbia University Mailman School of Public Health. Previously, from 2000 until late 2006, Dr. Rowe served as Chairman and CEO of Aetna, Inc., one of the nation's leading health care and related benefits organizations. Before his tenure at Aetna, from 1998 to 2000, Dr. Rowe served as President and Chief Executive Officer of Mount Sinai NYU Health, one of the nation's largest academic health care organizations. From 1988 to 1998, prior to the Mount Sinai-NYU Health merger, Dr.
Halle Tecco, MBA, MPH is a digital health investor who created the first MBA-level course on digital health investing in 2016 for Columbia Business School. Previously, she founded women’s health company Natalist (acquired by Everly Health) and seed fund Rock Health. She is an advisor to the Harvard Medical School Department of Biomedical Informatics and serves on the Boards of the International African American Museum and RESOLVE: The National Infertility Association.
